Sponsor:
UI Contact:
Updated Date:
The National Institutes of Health, through its NIH Guide, has recently published the following funding-related policy notices, general notices, notices of changes, notices of special interest NOSI, and funding opportunities.
Policy Notices
- Policy Update - Results Information Reporting for Applicable Clinical Trials (ACTs)
National Institutes of Health
- Upcoming Changes to the Notice of Award (NoA) Beginning October 1, 2020
National Institutes of Health
General Notices
- NCCIH Policy Change to Budget Limit and Grant Durations for SBIR/STTR Phase I and Phase II Applications
National Center for Complementary and Integrative Health
- Notice of information to PAR-18-746, " NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)"
National Institute on Drug Abuse
- Notice of Pre-Application Information Webinar for RFA-DA-21-009, "Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents (R01 - Clinical Trial Optional)"
National Institute on Drug Abuse
- Notice of Pre-Application Webinar for the Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium
National Institute of Diabetes and Digestive and Kidney Diseases
- Notice of Informational Webinar on the NIH Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Program Funding Opportunity Announcements (UE5 and K99/R00)
National Institute of General Medical Sciences
- Solicitation of Nominations for the 2021 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship
National Institute of Neurological Disorders and Stroke
- Accelerating Clinical Care and Research through the Use of the United States Core Data for Interoperability (USCDI)
National Institutes of Health
- Findings of Research Misconduct
National Institutes of Health
- Notice of Technical Assistance Webinars for Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) RFAs: RFA-RM-20-015, RFA-RM-20-016, RFA-RM-20-017, RFA-RM-20-018
Office of Strategic Coordination (Common Fund)
- Request for Information (RFI):Advancing Biomarker Research and Implementation to Personalize Health Services Delivery for Tobacco Use Disorder
National Institute on Drug Abuse
- Request for Information (RFI) on Clarification of Institutional Responsibilities Regarding Grant to Protocol Congruency
National Institutes of Health
Notice of Changes to Funding Opportunities
- Notice to Extend the Expiration Date of PAR-18-189 Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
- Notice to Extend the Expiration Date of PAR-18-190 Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
National Institute on Aging
- Notice of Termination: PAR-20-136 "Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)"
National Cancer Institute
- Notice of Extension of the Expiration Date of PAR-18-654 "Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)"
National Cancer Institute
- Notice of Extension of the Expiration Date of PAR-18-655 "Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
National Cancer Institute
- Notice of Correction to Eligibility Information in PAR-20-278 "NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)"
National Cancer Institute
- Notice of Change to Application Types Allowed in Funding Opportunity Announcement PAR-19-361 "Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)"
National Cancer Institute
- Notice of Correction to PAR-20-225, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
National Institute on Drug Abuse
- Notice of Correction to PAR-19-223, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
National Institute on Drug Abuse
- Notice of NIDCR's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)"
National Institute of Dental and Craniofacial Research
- NHLBI Withdraws Participation in NOT-MD-20-022 "Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations"
National Heart, Lung, and Blood Institute
- Notice of ORWH's and NICHD's Participation in PAR-20-179, "Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)"
Office of Research on Women's Health
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of ORWH's and NICHD's Participation in PAR-20-180, "Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)"
Office of Research on Women's Health
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Notices of Intent to Publish
- Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study
National Institute on Drug Abuse
- Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center (U54 Clinical Trial Not Allowed)
Office of Strategic Coordination (Common Fund)
- Notice of Intent to Publish a Funding Opportunity Announcement for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Not Allowed)
Office of Strategic Coordination (Common Fund)
Requests for Proposal
- Notice of Information: FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms in Understanding Tumor Heterogeneity
National Cancer Institute
Funding Opportunities
- Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)
Office of Dietary Supplements
National Center for Complementary and Integrative Health
National Cancer Institute
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
- Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)
National Human Genome Research Institute
National Cancer Institute
National Eye Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
Office of Behavioral and Social Sciences Research
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)
National Human Genome Research Institute
National Cancer Institute
National Eye Institute
National Institute on Aging
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Office of Behavioral and Social Sciences Research
- Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03) Clinical Trial Optional)
National Human Genome Research Institute
John E. Fogarty International Center
National Cancer Institute
National Institute on Aging
National Institute of Environmental Health Sciences
National Institute of Mental Health
Office of Behavioral and Social Sciences Research. - Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)
National Institute on Drug Abuse
National Institute on Alcohol Abuse and Alcoholism
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institute of Neurological Disorders and Stroke
- Transition to Aging Research for Predoctoral Students (F99/K00)
National Institute on Aging - Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)
National Institute on Aging
- Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Neurological Disorders and Stroke
- NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
National Institute of Diabetes and Digestive and Kidney Diseases
- Limited Competition: Data Coordinating Center (DCC) for Completion of Ongoing MFMU Network Protocols (U24 Clinical Trial Optional)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Limited Competition: Clinical Centers for Completion of Ongoing MFMU Network Protocols (UG1 Clinical Trial Optional)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01, Clinical Trial Optional)
National Human Genome Research Institute
National Cancer Institute
- Investigator-Initiated Research on Genetic Counseling Processes and Practices (R21, Clinical Trial Optional)
National Human Genome Research Institute
- The NINDS Human Biospecimen and Data Repository (U24 Clinical Trial Not Allowed)
National Institute of Neurological Disorders and Stroke
Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu or 335-2123, or email Carrie Damon at carolyn-damon@uiowa.edu or Dave Myers at dave-myers@uiowa.edu or Lynn Hudachek at lynn-hudachek @uiowa.edu